Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 62 results for neuropathic pain

  1. Potential for dependence associated with pharmacological drugs for neuropathic pain:- Is there a potential for dependence associated with pharmacological agents for neuropathic pain?

    pharmacological drugs for neuropathic pain:- Is there a potential for dependence associated with pharmacological agents for...

  2. Neuropathic pain relief:- Does early treatment with a centrally acting analgesic (for example pregabalin) reduce the frequency or severity of neuropathic pain in people with spinal cord injury?

    Recommendation ID NG41/1 Question Neuropathic pain relief:- Does early treatment with a centrally acting analgesic (for example...

  3. Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NG193)

    This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is pain with no clear underlying cause, or pain (or its impact) that is out of proportion to any observable injury or disease.

  4. Monotherapy versus combination therapy for treating neuropathic pain:- What is the clinical effectiveness, cost effectiveness and tolerability of pharmacological monotherapy compared with combination therapy for treating neuropathic pain?

    Question Monotherapy versus combination therapy for treating neuropathic pain:- What is the clinical effectiveness, cost effectiveness...

  5. Does early intervention to treat neuropathic pain reduce the likelihood of chronic pain?

    Question Does early intervention to treat neuropathic pain reduce the likelihood of chronic pain? Any explanatory notes(if...

  6. Is there a potential for dependence associated with pharmacological agents for neuropathic pain?

    potential for dependence associated with pharmacological agents for neuropathic pain? Any explanatory notes(if applicable) There has...

  7. How should the symptomatic treatment of neuropathic pain relate to its cause?

    CG173/7 Question How should the symptomatic treatment of neuropathic pain relate to its cause? Any explanatory notes(if applicable)

  8. What is the impact of drug-related adverse effects on health economics and quality of life in neuropathic pain?

    and quality of life in neuropathic pain? Any explanatory notes(if applicable) Pharmacological agents for neuropathic pain...

  9. What are the key factors, including additional care and support, that influence participation* and quality of life in people with neuropathic pain?

    support, that influence participation* and quality of life in people with neuropathic pain? Any explanatory notes(if applicable) * The...

  10. What is the clinical effectiveness, cost effectiveness and tolerability of pharmacological monotherapy compared with combination therapy for treating neuropathic pain?

    pharmacological monotherapy compared with combination therapy for treating neuropathic pain? Any explanatory notes(if applicable) Why...

  11. Factors affecting participation and quality of life:- What are the key factors, including additional care and support, that influence participation and quality of life in people with neuropathic pain?

    support, that influence participation and quality of life in people with neuropathic pain? Any explanatory notes(if applicable) Why this...

  12. Relationship between symptoms, cause of neuropathic pain and its treatment:- Is response to pharmacological treatment predicted more reliably by underlying aetiology or by symptom characteristics?

    CG173/2 Question Relationship between symptoms, cause of neuropathic pain and its treatment:- Is response to pharmacological treatment...

  13. Impact of drug-related adverse effects on cost effectiveness and quality of life:- What is the impact of drug-related adverse effects on health economics and quality of life in neuropathic pain?

    of life in neuropathic pain? Any explanatory notes(if applicable) Why this is important:- Pharmacological agents for neuropathic...

  14. Head and neck cancer (QS146)

    This quality standard covers assessing, diagnosing and managing head and neck cancer, including cancer of the upper aerodigestive tract in people aged 16 and over. It describes high-quality care in priority areas for improvement.

  15. Spinal cord stimulator implantation: Improving theatre efficiency

    availability of beds and workforce challenges” (NHS Improvement 2019). NHS Pain Departments, along with other specialties, struggle for...